People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Denali Therapeutics Inc. | — | Biotechnology | Growth/Late | $499.7M | $7.2B | 2024 |
Marc P. Tessier-Lavigne at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc P. Tessier-Lavigne on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter S. Klein | 1 | 2 |
| Ryan Watts | 1 | 2 |
| Vicki L. Sato | 1 | 1 |
| Nancy A. Thornberry | 1 | 1 |
| Jay T. Flatley | 1 | 1 |
| David P. Schenkein | 1 | 1 |
| Erik T. Harris | 1 | 1 |
| Steve E. Krognes | 1 | 1 |
| Jennifer O. Cook | 1 | 1 |
| Alexander O. Schuth | 1 | 1 |
| Carole O. Ho | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.